FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2558582800> ?p ?o ?g. }

• W2558582800 endingPage "1579" @default.
• W2558582800 startingPage "1569" @default.
• W2558582800 abstract "// Chia-Lin Lee 1, 2, 3, 4 , Chun-Hao Tsai 5, 6 , Dah-Cherng Yeh 7 , Chi-Shy Lin 8 , Yu-Fen Li 4 , Huey-En Tzeng 6, 9, 10 1 Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital, Taiwan 2 Department of Public Health, College of Public Health, China Medical University, Taichung, Taiwan 3 Department of Medical Research, Taichung Veterans General Hospital, Taiwan 4 Graduate Institute of Biostatistics, China Medical University, Taichung, Taiwan 5 Department of Orthopedics, China Medical University Hospital, Taichung, Taiwan 6 School of Medicine, China Medical University, Taichung, Taiwan 7 Department of Surgery, Taichung Tzu Chi General Hospital, Taichung, Taiwan 8 Department of Family Medicine, Taichung Veterans General Hospital, Taiwan 9 Division of Hematology/Oncology, Department of Medicine, Taichung Veterans General Hospital, Taichung, Taiwan 10 Breast Cancer Center, Taichung Veterans General Hospital, Taiwan Correspondence to: Yu-Fen Li, email: yufenli@mail.cmu.edu.tw Huey-En Tzeng, email: tzenghueyen@gmail.com Keywords: breast cancer, hemoglobin, survival, trajectory Received: October 06, 2016      Accepted: November 08, 2016      Published: November 29, 2016 ABSTRACT Hemoglobin (Hb) levels are reportedly related with treatment outcomes and survival in patients of breast cancer. However, the long-term change in Hb levels after treatment and the effects of Hb on survival remain unknown. This retrospective cohort study enrolled 1931 breast cancer patients with pathological stage I-IV between 1/1/2003 and 12/31/2013. Latent class modeling was used to identify trajectories in monthly Hb levels over time. The primary endpoint was 10-year cancer-related death. We identified 5 distinct Hb trajectories: persistent anemia (5.6 %; n = 109), improved anemia (4.8 %, n = 93), mild anemia (21.0%; n = 406), low normal Hb (46.6 %; n = 899), and normal Hb (21.9%; n = 424). Compared with the normal-Hb group, trajectories with low Hb levels had worst 10-year survival. The adjusted hazard ratios were 1.79(95% CI, 0.91-3.53) for the improved anemia group, 1.09(95% CI, 0.68-1.74) for the mild anemia group, 1.06 (95% CI, 0.71-1.60) for the low normal Hb group, and 2.19(95% CI 1.28-3.75) for the persistent anemia group. Our findings show there are five Hb level trajectories during breast cancer treatment. The anemia Hb level trajectory during the first 12 months after treatment reflect the worst cancer-related 10-year survival in breast cancer patients." @default.
• W2558582800 created "2016-12-08" @default.
• W2558582800 creator A5004695493 @default.
• W2558582800 creator A5033640621 @default.
• W2558582800 creator A5038610896 @default.
• W2558582800 creator A5042251677 @default.
• W2558582800 creator A5042586622 @default.
• W2558582800 creator A5083128658 @default.
• W2558582800 date "2016-11-29" @default.
• W2558582800 modified "2023-10-15" @default.
• W2558582800 title "Hemoglobin level trajectories in the early treatment period are related with survival outcomes in patients with breast cancer" @default.
• W2558582800 cites W1543235639 @default.
• W2558582800 cites W1546478791 @default.
• W2558582800 cites W1966031562 @default.
• W2558582800 cites W1971995358 @default.
• W2558582800 cites W1978506033 @default.
• W2558582800 cites W1982941212 @default.
• W2558582800 cites W1983306435 @default.
• W2558582800 cites W1987535825 @default.
• W2558582800 cites W1997006461 @default.
• W2558582800 cites W2002355437 @default.
• W2558582800 cites W2020105314 @default.
• W2558582800 cites W2023338540 @default.
• W2558582800 cites W2023554081 @default.
• W2558582800 cites W2033363278 @default.
• W2558582800 cites W2034125442 @default.
• W2558582800 cites W2039412091 @default.
• W2558582800 cites W2043536053 @default.
• W2558582800 cites W2054333460 @default.
• W2558582800 cites W2060370948 @default.
• W2558582800 cites W2060418938 @default.
• W2558582800 cites W2065739714 @default.
• W2558582800 cites W2067167890 @default.
• W2558582800 cites W2075345186 @default.
• W2558582800 cites W2085246966 @default.
• W2558582800 cites W2087627934 @default.
• W2558582800 cites W2098908259 @default.
• W2558582800 cites W2103571989 @default.
• W2558582800 cites W2108451834 @default.
• W2558582800 cites W2115773204 @default.
• W2558582800 cites W2118150784 @default.
• W2558582800 cites W2118655588 @default.
• W2558582800 cites W2127303778 @default.
• W2558582800 cites W2127990020 @default.
• W2558582800 cites W2135751749 @default.
• W2558582800 cites W2139331374 @default.
• W2558582800 cites W2140391009 @default.
• W2558582800 cites W2142002753 @default.
• W2558582800 cites W2159923585 @default.
• W2558582800 cites W2168014041 @default.
• W2558582800 cites W2169991667 @default.
• W2558582800 cites W2189483181 @default.
• W2558582800 cites W2253456471 @default.
• W2558582800 cites W2275040472 @default.
• W2558582800 cites W2327922861 @default.
• W2558582800 cites W2414484987 @default.
• W2558582800 cites W4235367200 @default.
• W2558582800 cites W4296277331 @default.
• W2558582800 cites W4362223593 @default.
• W2558582800 doi "https://doi.org/10.18632/oncotarget.13679" @default.
• W2558582800 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5352078" @default.
• W2558582800 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27906669" @default.
• W2558582800 hasPublicationYear "2016" @default.
• W2558582800 type Work @default.
• W2558582800 sameAs 2558582800 @default.
• W2558582800 citedByCount "9" @default.
• W2558582800 countsByYear W25585828002019 @default.
• W2558582800 countsByYear W25585828002020 @default.
• W2558582800 countsByYear W25585828002021 @default.
• W2558582800 countsByYear W25585828002022 @default.
• W2558582800 crossrefType "journal-article" @default.
• W2558582800 hasAuthorship W2558582800A5004695493 @default.
• W2558582800 hasAuthorship W2558582800A5033640621 @default.
• W2558582800 hasAuthorship W2558582800A5038610896 @default.
• W2558582800 hasAuthorship W2558582800A5042251677 @default.
• W2558582800 hasAuthorship W2558582800A5042586622 @default.
• W2558582800 hasAuthorship W2558582800A5083128658 @default.
• W2558582800 hasBestOaLocation W25585828001 @default.
• W2558582800 hasConcept C121608353 @default.
• W2558582800 hasConcept C126322002 @default.
• W2558582800 hasConcept C512399662 @default.
• W2558582800 hasConcept C530470458 @default.
• W2558582800 hasConcept C71924100 @default.
• W2558582800 hasConceptScore W2558582800C121608353 @default.
• W2558582800 hasConceptScore W2558582800C126322002 @default.
• W2558582800 hasConceptScore W2558582800C512399662 @default.
• W2558582800 hasConceptScore W2558582800C530470458 @default.
• W2558582800 hasConceptScore W2558582800C71924100 @default.
• W2558582800 hasIssue "1" @default.
• W2558582800 hasLocation W25585828001 @default.
• W2558582800 hasLocation W25585828002 @default.
• W2558582800 hasLocation W25585828003 @default.
• W2558582800 hasLocation W25585828004 @default.
• W2558582800 hasOpenAccess W2558582800 @default.
• W2558582800 hasPrimaryLocation W25585828001 @default.
• W2558582800 hasRelatedWork W2014447844 @default.
• W2558582800 hasRelatedWork W2091020218 @default.
• W2558582800 hasRelatedWork W2113427382 @default.

• next